Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer (TNBC).

The biggest challenge facing immunotherapy in TNBC is proving that it works, says Curigliano.

The IMpassion130 trial is a prospective randomized trial that is comparing nab-paclitaxel (Abraxane) alone versus nab-paclitaxel plus atezolizumab (Tecentriq). It is currently ongoing.

Curigliano adds that data from neoadjuvant trials will be very important, as they may demonstrate that the addition of an immune checkpoint inhibitor increases pathologic complete response in patients with metastatic disease.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Immuno-Oncology

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses immunotherapy trials in triple-negative breast cancer.

Dr. Curigliano Discusses Immunotherapy Trials in Breast Cancer